Fate Therapeutics Inc financial data

Symbol
FATE on Nasdaq
Location
12278 Scripps Summit Drive, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 803 % -7.16%
Return On Equity -56.6 % -23.4%
Return On Assets -40.2 % -18.3%
Operating Margin -2.45K % -67.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares +1.28%
Common Stock, Shares, Outstanding 115M shares +1.28%
Entity Public Float 369M USD -20.1%
Common Stock, Value, Issued 115K USD +0.88%
Weighted Average Number of Shares Outstanding, Basic 119M shares +1.04%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +1.04%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.14M USD -46.9%
Research and Development Expense 116M USD -12.9%
General and Administrative Expense 51.1M USD -33.5%
Operating Income (Loss) -175M USD +11.1%
Net Income (Loss) Attributable to Parent -156M USD +12.4%
Earnings Per Share, Basic -1 USD/shares +20%
Earnings Per Share, Diluted -1 USD/shares +20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.6M USD +7.16%
Accounts Receivable, after Allowance for Credit Loss, Current 682K USD -83.5%
Assets, Current 221M USD -28.7%
Property, Plant and Equipment, Net 59.5M USD -27.8%
Operating Lease, Right-of-Use Asset 42.4M USD -27.4%
Other Assets, Noncurrent 0 USD -100%
Assets 344M USD -30.6%
Accounts Payable, Current 3.5M USD -44.8%
Accrued Liabilities, Current 17.6M USD -25.5%
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 28.1M USD -24.9%
Operating Lease, Liability, Noncurrent 74.5M USD -19.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 153K USD -81.7%
Retained Earnings (Accumulated Deficit) -1.5B USD -11.6%
Stockholders' Equity Attributable to Parent 234M USD -35.4%
Liabilities and Equity 344M USD -30.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.8M USD -1.38%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 42.7M USD +146%
Common Stock, Shares Authorized 350M shares +40%
Common Stock, Shares, Issued 115M shares +1.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.86M USD -88.8%
Deferred Tax Assets, Valuation Allowance 362M USD +11.8%
Deferred Tax Assets, Gross 374M USD +9.18%
Operating Lease, Liability 79.2M USD -19.9%
Payments to Acquire Property, Plant, and Equipment 1.2M USD +1291%
Lessee, Operating Lease, Liability, to be Paid 122M USD -19.5%
Property, Plant and Equipment, Gross 99.5M USD -31.1%
Operating Lease, Liability, Current 4.75M USD -31.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.4M USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.1M USD -26.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 43.1M USD -18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.3M USD -35.7%
Deferred Tax Assets, Operating Loss Carryforwards 147M USD +30.3%
Preferred Stock, Shares Issued 2.76M shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 70.5M USD +18.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.6M USD -29.6%
Additional Paid in Capital 1.74B USD +1.67%
Preferred Stock, Shares Outstanding 2.76M shares
Depreciation, Depletion and Amortization 3.33M USD -30.9%
Share-based Payment Arrangement, Expense 28.5M USD -31.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%